An update on the management of chronic hepatitis D  

慢性丁型肝炎的最新治疗进展

作　　者：Pir Ahmad Shah Saad Choudhry Karen J.Campoverde Reyes Daryl T.Y.Lau 

机构地区：[1]Division of Gastroenterology,Beth Israel Deaconess Medical Center,Harvard Medical School,Boston,MA,USA [2]Neuroendocrine Unit,Massachusetts General Hospital,Harvard Medical School,Boston,MA,USA

出　　处：《Gastroenterology Report》2019年第6期396-402,I0001,共8页胃肠病学报道（英文）

摘　　要：Hepatitis D virus(HDV)infection is associated with severe liver-related morbidity and mortality.The prevalence of HDV is rising especially among people who abuse drugs and immigrants from endemic areas.Reliable diagnostic assays with enhanced sensitivity and specificity are essential for screening at-risk populations.Until recently,interferon has been the only treatment for hepatitis D.Its efficacy is,however,limited and it is associated with significant side effects.A number of novel antiviral agents that target various stages of the HDV life cycle show promising results.They are currently in different phases of clinical development.This review focuses on the changing epidemiology,novel therapeutic agents,and updated management of chronic hepatitis delta.丁型肝炎病毒感染(HDV)会导致严重的并发症甚至是患者死亡。HDV发病率一直在上升,尤其是在那些吸毒者及高发地区的移民中。需要采用一些高灵敏度、高特异度的诊断方法对这些人群进行筛查。截至目前,干扰素仍然是丁型肝炎唯一的治疗药物,然而,其疗效有限且不良反应明显。一些靶向HDV生命周期不同阶段的抗病毒药物已经显示出了良好的结果,这些药物目前分处于临床研究的不同阶段。本文着重讨论了慢性丁型肝炎流行病学特征的变化、新的治疗药物及最新的治疗推荐。

关 键 词：chronic hepatitis D HDV therapy HDV diagnostics INTERFERON myrcludex B LONAFARNIB 

分 类 号：R512.64[医药卫生—内科学]